**Patient Discharge Summary**

**Patient Information:**

* Name: John Doe
* Date of Birth: March 12, 1990
* Admission Date: March 10, 2023
* Discharge Date: March 20, 2023
* Patient ID: 123456

**Clinical Summary:**

John Doe, a 33-year-old male, was admitted to the endocrinology unit on March 10, 2023, with symptoms of increased thirst, frequent urination, and weight loss. He was diagnosed with type 1 diabetes mellitus after a comprehensive evaluation, including fasting plasma glucose (FPG) levels, glycosylated hemoglobin (HbA1C) testing, and oral glucose tolerance testing (OGTT).

**Diagnosis and Treatment:**

The patient's FPG levels were 350 mg/dL (19.4 mmol/L), and HbA1C was 12.1%. OGTT revealed a peak glucose level of 450 mg/dL (25 mmol/L) at 120 minutes. The patient was diagnosed with type 1 diabetes mellitus, and insulin therapy was initiated.

The patient was started on a basal-bolus insulin regimen, consisting of:

* Lantus (insulin glargine) 20 units subcutaneously at 8:00 PM
* NovoLog (insulin aspart) 10 units subcutaneously before meals (3 times a day)

The patient was also prescribed metformin 500 mg orally twice a day to help improve glycemic control.

**Hospital Course:**

The patient's hospital course was marked by close monitoring of his blood glucose levels, which were managed with adjustments to his insulin dosages. He developed mild hypoglycemia on day 3 of admission, which was treated with glucagon injection. His blood glucose levels stabilized by day 5, and he was able to tolerate a regular diet.

**Education and Counseling:**

The patient received comprehensive education and counseling on diabetes management, including:

* Diet: A personalized meal plan focusing on whole foods, high-quality carbohydrates, and portion control was provided.
* Exercise: The patient was advised to engage in physical activity of at least 150 minutes per week, with adjustments to insulin dosages as needed.
* Monitoring: The patient was instructed to self-monitor his blood glucose levels 4-6 times a day, using a glucometer.
* Medication: The patient was educated on the proper use of his insulin pen and the importance of taking his medications as prescribed.
* Complications: The patient was informed about the importance of regular foot examinations, funduscopic examinations, and lipid profile checks to monitor for diabetic complications.

**Discharge Instructions:**

The patient was discharged on March 20, 2023, with the following instructions:

* Continue taking Lantus 20 units subcutaneously at 8:00 PM and NovoLog 10 units subcutaneously before meals (3 times a day)
* Take metformin 500 mg orally twice a day
* Monitor blood glucose levels 4-6 times a day and adjust insulin dosages as needed
* Attend regular follow-up appointments with his endocrinologist
* Schedule a podiatric evaluation within 2 weeks of discharge
* Receive a flu shot and pneumonia vaccine within the next 2 weeks

**Follow-up:**

The patient is scheduled for a follow-up appointment with his endocrinologist on April 10, 2023, to monitor his blood glucose levels and adjust his treatment plan as needed.

**Final Diagnosis:**

Type 1 diabetes mellitus

**Treatment Plan:**

* Basal-bolus insulin regimen
* Metformin 500 mg orally twice a day
* Regular monitoring and adjustments to insulin dosages as needed
* Comprehensive education and counseling on diabetes management

**Discharge Summary Signature:**

[Signature of Discharging Physician]

**Date:** March 20, 2023